----
Current ValuationThe current P/E ratio is -11.37, below the reasonable range, cheaper than 96.32% of the time in the past 5 years, and the industry ranks 132/174, the industry Median -0.98.
-11.37xP/E
$5.06Stock price
$-0.44Earnings per share
-11.37xP/E
Stock price$5.06Earnings per share$-0.44
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.97x
- Typical range
- -5.70x–-0.93x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -11.78x | 141.71% | $12.52B |
GKOSUSGlaukos | -51.44x | 75.37% | $9.67B |
TFXUSTeleflex | -5.14x | 118.39% | $5.31B |
PLSEUSPulse Biosciences | -44.99x | 27.55% | $3.60B |
IRTCUSIRhythm | -257.83x | 73.29% | $3.60B |
BFLYUSButterfly Network | -33.37x | 34.41% | $2.50B |
AXGNUSAxogen | -65.09x | 18.38% | $2.18B |
ASSTUSStrive | -2.15x | 63.23% | $2.09B |
NVCRUSNovocure | -11.91x | 1.23% | $1.77B |
KMTSUSKestra Medical Tech | -11.08x | 0.94% | $1.66B |
ATECUSAlphatec | -15.05x | 41.67% | $1.66B |
DRTSUSAlpha Tau Medical | -14.85x | -- | $1.37B |
TNDMUSTandem Diabetes | -18.15x | 77.60% | $1.15B |
AORTUSArtivion | -345.46x | 266.67% | $1.10B |
ENOVUSEnovis | -0.98x | 100.97% | $1.08B |
IARTUSIntegra LifeSciences | -142.82x | 109.42% | $1.03B |
PRCTUSPROCEPT BioRobotics | -9.30x | 3.47% | $1.02B |
BBNXUSBeta Bionics | -13.67x | 13.22% | $997.56M |
CBLLUSCeribell | -14.46x | 35.15% | $954.08M |
SIBNUSSI-BONE | -60.68x | 8.85% | $887.86M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
